LeonaBio Q2 FY26 net loss widens to $19 million; R&D expenses more than doubled to $12.9 million

• LeonaBio posted a net loss of $19 million, or $0.80 per share, for the quarter ended June 30, 2026.
• R&D expense more than doubled to $12.9 million, driven primarily by higher ELAINE-3 clinical trial spending.
• G&A costs rose to $6.6 million from $3.6 million a year earlier on higher personnel-related and professional service expenses.
• Cash, cash equivalents and investments fell to $51.1 million as of June 30, 2026, from $88.3 million at end-2025.
• ELAINE-3 enrolled 495 patients; enrollment of about 600 remains on track for 4Q 2026 with topline data expected in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeonaBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141605PRIMZONEFULLFEED9810577) on August 14, 2026, and is solely responsible for the information contained therein.